Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Total Non-current Liabilities
All obligations due after more than one year.
Maze Therapeutics, Inc.NASDAQ: MAZE
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 156.3% from a year ago
Total non-current liabilities stood at $56.77M at the end of Q1 FY2026, up 156.3% from a year earlier and up 189.6% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.
Context
- Total non-current liabilities amounted to 13.5% of total assets at the end of Q1 FY2026, up 6.9 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +156.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 19.61M USD
- Year-over-year change
- -14.6%
- 3-year CAGR
- -10.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.61M | -14.6% |
| FY2024 | 2024-12-31 | 22.97M | -49.1% |
| FY2023 | 2023-12-31 | 45.13M | +62.8% |
| FY2022 | 2022-12-31 | 27.73M | — |
Total Non-current Liabilities vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +156.3% is the highest of 8, against a peer median of +19.5%.
- Total non-current liabilities amounts to 13.5% of total assets for MAZE, versus a peer median of 48.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.64B USD | +19.5% | +9.1% | 81.4% | |
| Sep 2026 | $614.73M USD | +86.3% | -12.2% | 72.5% | |
| Mar 2026 | $246.32M USD | +30.5% | +111.2% | 48.8% | |
| Dec 2025 | €200.57M EUR | +91.2% | +71.4% | 80.6% | |
SEPNSepterna, Inc. | Sep 2026 | $86.61M USD | -39.3% | +19.4% | 14.0% |
| Mar 2026 | $56.77M USD | +156.3% | -10.9% | 13.5% | |
BIOABioAge Labs, Inc. | Mar 2026 | $2.71M USD | -61.0% | -72.9% | 0.7% |
| Mar 2026 | $97K USD | -54.0% | -31.6% | 0.2% | |
| Peer median (excluding MAZE) | — | +19.5% | +9.1% | 48.8% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.